Latest Sigma-Aldrich Stories

ST. LOUIS, March 15, 2012 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL), will hold its Business Review with the financial community on Thursday, March 29, 2012 at 8:30 AM Central Time and 9:30 AM Eastern Time. Presenters will include: President & CEO Rakesh Sachdev; Vice President & Treasurer Kirk Richter; EVP & President, SAFC Gilles Cottier; EVP & President Research Frank Wicks; Chief Scientific Officer Dave Smoller; Vice President & Managing...

ST. LOUIS, March 14, 2012 /PRNewswire/ -- SAFC Hitech®, a member of the Sigma-Aldrich® Group, today underlined its commitment to the Asia-Pacific electronics markets with the opening of its new multi-million US dollar facility in Kaohsiung, Taiwan. The 270,000 sq ft( )expansion significantly increases the site's existing capacity for the high-volume manufacturing of high-quality Trimethylgallium (TMG), Triethylgallium (TEG) and Trimethylindium (TMI) precursors for High Brightness...

ST. LOUIS, Feb. 23, 2012 /PRNewswire/ -- Sigma-Aldrich is pleased to announce the appointment of Jan Bertsch (age 55) as Executive Vice President and Chief Financial Officer (CFO) effective March 5, 2012. Prior to her appointment at Sigma-Aldrich, Ms. Bertsch was employed by BorgWarner, most recently as Vice President, Controller and Principal Accounting Officer, having previously served as Vice President and Treasurer. Prior to her employment with BorgWarner, Ms. Bertsch served as...

ST. LOUIS, Mo., Feb. 21, 2012 /PRNewswire/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL) today announced that Sigma Life Science, its innovative biological products and services research business, has furthered its commitment to stem cell research, drug discovery and ADME/Toxicology by acquiring a worldwide license to use Kyoto University's induced pluripotent stem (iPS) cell patent portfolio. Sigma Life Science, leveraging its zinc finger protein platform and stem cell technology...

ST. LOUIS, Feb. 14, 2012 /PRNewswire/ -- At a meeting held today, the Directors increased the Company's quarterly cash dividend by 11.1% to $0.20 per share. The dividend is payable on March 15, 2012 to shareholders of record on March 1, 2012. About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research,...

RICHMOND, Calif., Feb. 9, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 2:30 pm ET on Thursday, February 16, 2012, at the 2012 Leerink Swann Global Healthcare Conference which will be held in New York City. The presentation will be webcast live and may be...

ST. LOUIS, Feb. 9, 2012 /PRNewswire/ -- HIGHLIGHTS: 2011 Results (all percentages are to comparable periods in 2010) Q4 Results Reported sales increased 5% to $610 million. Sales grew organically by 3% with Research and Fine Chemicals ("SAFC") sales growing organically by 1% and 7%, respectively. Acquisitions contributed 2% to sales growth.Net income was $108 million, up 15% from Q4 2010.Reported diluted EPS was $0.89, up 17% from Q4 2010. Excluding a one-time tax item in 2011 adjusted...

RICHMOND, Calif., Feb. 1, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and full year 2011 financial results on Wednesday, February 8, 2012, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business...

ST. LOUIS, Jan. 31, 2012 /PRNewswire/ -- From: Rakesh Sachdev, President and CEO: Sigma-Aldrich Corporation (NASDAQ:SIAL), a leading Life Science and High Technology company, announced it has completed its acquisition of BioReliance Holdings, Inc., a leading provider of global biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash, subject to normal post-closing adjustments. BioReliance provides critical services that include...

ST. LOUIS, Jan. 27, 2012 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL) will be presenting at the following investor conferences in February: Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16, 2012, at the Waldorf Astoria Hotel, New York, NY, presenting at 9:00 A.M. (EST). Citi 2012 Global Healthcare Conference on Monday, February 27, 2012, at the Waldorf Astoria Hotel, New York, NY, presenting at 2:00 P.M. (EST) (Logo:...